Publications by authors named "Eti Ishai"

Focal segmental glomerulosclerosis (FSGS) is a scarring process associated with chronic low-grade inflammation ascribed to toll-like receptor (TLR) activation and monocyte migration. We developed synthetic, small-molecule lecinoxoids, VB-201 and VB-703, that differentially inhibit TLR-2- and TLR-4-mediated activation and monocyte migration. The efficacy of anti-inflammatory lecinoxoid treatment on FSGS development was explored using a 5/6 nephrectomy rat model.

View Article and Find Full Text PDF

Binding of chemokines to their cognate receptors on monocytes instigates a cascade of events that directs these cells to migrate to sites of inflammation and cancerous tissues. Although targeting of selected chemokine receptors on monocytes exhibited preclinical efficacy, attempts to translate these studies to the clinic have failed thus far, possibly due to redundancy of the target receptor. We reveal that motile sperm domain-containing protein 2 (MOSPD2), a protein with a previously unknown function, regulates monocyte migration in vitro.

View Article and Find Full Text PDF

Background And Aims: Previous studies demonstrated that toll-like receptors 4 and 2 (TLR-4 and TLR-2), which are expressed on liver-resident Kupffer, hepatic stellate cells, and circulating monocytes, play a role in nonalcoholic fatty liver disease. Lecinoxoids are oxidized phospholipids that antagonize TLR-2- and TLR-4-mediated activation of innate immune cells and inhibit monocyte migration. In this study, we tested the effect of two functionally different lecinoxoids on the development of nonalcoholic steatohepatitis and liver fibrosis in a mouse model.

View Article and Find Full Text PDF
Article Synopsis
  • Oxidized phospholipids (Ox-PLs), typically associated with inflammation, may also have anti-inflammatory effects.
  • A synthetic Ox-PL analog called VB-201 was tested for its benefits on autoimmune inflammatory disease in the central nervous system (CNS).
  • Oral treatment with VB-201 reduced the severity of autoimmune encephalomyelitis (EAE) and inhibited the activation of T-cells responsible for the disease, suggesting a new potential for Ox-PLs in treating CNS inflammatory conditions.
View Article and Find Full Text PDF